Moody’s downgrades Senegal to Caa1 amid rising debt concerns
MoonLake Immunotherapeutics (NASDAQ:MLTX) Chief Financial Officer Matthias Bodenstedt, recently purchased 10,870 shares of the company’s stock for approximately $98,808. The purchases were made on October 8, 2025, at prices ranging from $9.085 to $9.091244 per share.
Following the transaction, Bodenstedt directly owns 627,536 shares of MoonLake Immunotherapeutics. According to InvestingPro data, the company maintains a strong liquidity position with more cash than debt on its balance sheet, though its RSI suggests oversold conditions. Get access to 13 more exclusive InvestingPro Tips and comprehensive analysis in the Pro Research Report for MLTX.
In other recent news, Moonlake Immunotherapeutics has faced a series of significant developments following its Phase 3 VELA clinical trial results for its sonelokimab (SLK) treatment. The trials produced mixed outcomes, with the VELA-2 trial missing its primary endpoint due to a higher placebo effect, raising concerns about the regulatory path forward. As a result, several financial firms have adjusted their outlooks on the company’s stock. Oppenheimer lowered its price target from $104.00 to $25.00, maintaining an Outperform rating. H.C. Wainwright downgraded the stock from Buy to Neutral, citing the disappointing trial data. Needham also reduced its price target to $20.00 from $66.00, while maintaining a Buy rating. Guggenheim followed suit, cutting its target from $80.00 to $20.00 but still holding a Buy rating. Clear Street made the most dramatic adjustment, slashing its price target from $108.00 to $12.00, though it continues to recommend buying the stock. These developments have led to increased scrutiny and uncertainty around Moonlake’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.